Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
The Role of Cancer Stem Cells in Cancer Targeted Therapy
share announcement

The Role of Cancer Stem Cells in Cancer Targeted Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: closed (10 October 2023) | Viewed by 5459

Special Issue Editor

Dr. Faris Farassati

E-Mail Website
Guest Editor
Medicine Department of Medicine-Molecular Medicine Laboratory, The University of Kansas Medical Center, Kansas City, MO, USA
Interests: pro-oncogenic cell signaling machinery, oncolytic viruses; cancer stem cells (CSCs); cancer therapy

Special Issue Information

Dear Colleagues,

Most tumors appear to contain heterogeneous populations of cancer cells and cancer stem cells (CSC). These CSCs are more resistant to apoptosis, survive chemotherapy and eventually give rise to secondary tumors, which are harder to eliminate after the first-line of treatment. The reasons for resilience of CSCs to therapy are not well known at present. Understanding the biology of tumors and their CSCs will aid in developing novel anti-cancer therapies. This special issue reviews pro-oncogenic signaling pathways involved in the biology of CSCs along with novel therapeutic strategies to target these cells. The therapeutic strategies include drug and gene therapy approaches that have proven to be effective and specific.

With advancement of our understanding about Cancer Stem Cells, their eventual value as targets for cancer therapy has become an important area in molecular oncology and cancer therapeutics. On such basis, I am pleased to invite you to participate in an special issue of CANCERS which aims to demystify this novel field. This special issue aims to provide the reader with an appropriate level of understanding about important biological and genetic features of cancer stem cells along with the translational strategies that usurp such features to target these cells. Within this issue you will find drug and gene therapy based strategies that target cancer stem cells. Special articles will also focus on certain tumor types and the level of knowledge about cancer stem cells.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  1. Cancer stem cell (CSC) biology
  2. Molecular genetics of CSCs
  3. Markers of CSCs
  4. Pro-oncogenic pathways involved in CSCs biology
  5. Therapeutic strategies targeting CSCs
  6. Drug therapies targeting CSCs
  7. Genetic therapies targeting cancer stem cells
  8. Oncolytic viruses targeting CSCs
  9. Immune based therapies targeting cancer stem cells
  10. Tumor specific attempts to target CSCs

We look forward to receiving your contributions.

Dr. Faris Farassati
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Cancer stem cells
  • gene
  • therapy
  • marker
  • CSC
  • CD133
  • pathways
  • oncogenes
  • signaling
  • targeted therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

20 pages, 1597 KiB  
Article
Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis
by Tarinee Rungjirajittranon, Theerapat Siriwannangkul, Smith Kungwankiattichai, Nattawut Leelakanok, Wannaphorn Rotchanapanya, Pongthep Vittayawacharin, Benjamaporn Mekrakseree, Kamolchanok Kulchutisin and Weerapat Owattanapanich
Cancers 2022, 14(21), 5239; https://doi.org/10.3390/cancers14215239 - 26 Oct 2022
Cited by 3 | Viewed by 1969
Abstract
Acute myeloid leukemia (AML) with mutated RUNX1 (RUNX1mut) is considered to have an unfavorable prognosis. However, recent studies have reported comparable survival outcomes with wild-type RUNX1 (RUNX1wt). To assess the clinical outcomes of AML with and without [...] Read more.
Acute myeloid leukemia (AML) with mutated RUNX1 (RUNX1mut) is considered to have an unfavorable prognosis. However, recent studies have reported comparable survival outcomes with wild-type RUNX1 (RUNX1wt). To assess the clinical outcomes of AML with and without RUNX1mut, we performed a prospective cohort study and systematic review and meta-analysis. The study enrolled 135 patients (27 with RUNX1mut; 108 with RUNX1wt). There were no significant differences in the median OS and RFS of the RUNX1mut and RUNX1wt groups (9.1 vs. 12.2 months; p = 0.268 and 7.8 vs. 14.6 months; p = 0.481, respectively). A subgroup analysis of de novo AML patients with intermediate-risk cytogenetics showed similar outcomes. Our meta-analysis pooled data from 23 studies and our study. The complete remission rate was significantly lower in the RUNX1mut group (pooled odds ratio: 0.42). The OS, RFS, and event-free survival rates also favored the RUNX1wt group (pooled risk ratios: 1.36, 1.37, and 1.37, respectively). A subgroup analysis of de novo AML patients with intermediate-risk cytogenetics demonstrated nearly identical OS and RFS outcomes. This study confirms that patients with AML and RUNX1mut had poor prognoses. Nonetheless, in de novo AML with intermediate-risk cytogenetics, the survival outcomes of both groups were comparable. Full article
(This article belongs to the Special Issue The Role of Cancer Stem Cells in Cancer Targeted Therapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

23 pages, 2487 KiB  
Review
Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer
by Samantha Gogola, Michael Rejzer, Hisham F. Bahmad, Ferial Alloush, Yumna Omarzai and Robert Poppiti
Cancers 2023, 15(5), 1621; https://doi.org/10.3390/cancers15051621 - 6 Mar 2023
Cited by 8 | Viewed by 2916
Abstract
Prostate cancer (PCa) is the second-most commonly diagnosed cancer in men around the world. It is treated using a risk stratification approach in accordance with the National Comprehensive Cancer Network (NCCN) in the United States. The main treatment options for early PCa include [...] Read more.
Prostate cancer (PCa) is the second-most commonly diagnosed cancer in men around the world. It is treated using a risk stratification approach in accordance with the National Comprehensive Cancer Network (NCCN) in the United States. The main treatment options for early PCa include external beam radiation therapy (EBRT), brachytherapy, radical prostatectomy, active surveillance, or a combination approach. In those with advanced disease, androgen deprivation therapy (ADT) is considered as a first-line therapy. However, the majority of cases eventually progress while receiving ADT, leading to castration-resistant prostate cancer (CRPC). The near inevitable progression to CRPC has spurred the recent development of many novel medical treatments using targeted therapies. In this review, we outline the current landscape of stem-cell-targeted therapies for PCa, summarize their mechanisms of action, and discuss avenues of future development. Full article
(This article belongs to the Special Issue The Role of Cancer Stem Cells in Cancer Targeted Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop